Evaluation of factors affecting patients' refusal of HCV treatment in a cohort of Egyptian patients.

Abstract

BACKGROUND:

Treatment refusal, defined as active refusal of a patient to receive treatment despite physician recommendations, has not been extensively evaluated before in hepatitis C virus in the era of direct acting antivirals.

OBJECTIVE:

To investigate the reasons for refusal to receive hepatitis C virus treatment in Egypt.

METHODS:

an observational study conducted between July 2018 and November 2019 in Egypt. Enrollment was done to all patients who refused to get hepatitis C virus treatment during the national screening and treatment campaign. Reasons for their refusal were identified using a questionnaire as an instrument for data collection.

RESULTS:

Out of the 220 280 Egyptian hepatitis C virus patients who did not show up to start treatment and were contacted to get therapy, only 84 patients (0.038%) refused to receive treatment. The main reason for their refusal was having concerns about treatment (82.14%) and their main concern was the fear of adverse events (85.5%). Other causes of refusal were non-satisfactory experience at treatment centers (13.09%) and patients preferred to receive complementary and alternative medicines (4.7%). Most patients (65.4%) trusted the efficacy of directly acting antivirals for hepatitis C. None of the study participants was found to suffer from any psychiatric morbidity and the average score of the GHQ-12 was 10.7155.

CONCLUSION:

Proper health education and awareness regarding hepatitis C virus treatment safety and efficacy is needed to increase treatment acceptance rates.

• Authors: Mohamed B Hashem, Hedy A Badary, Noha A Mahfouz, Shaden Adel, Mohamed Alboraie, Mohamed AbdAllah, Wafaa AlAkel, Ramy Saeed, Islam Ammar, Wael Abdel-Razek, Mohamed Hassany, Gamal Esmat
• Journal: Journal of public health (Oxford, England) (J Public Health (Oxf)) Vol. 45 Issue 1 Pg. 214-217 (03 14 2023) ISSN: 1741-3850 [Electronic] England
• PMID: 34651189 (Publication Type: Observational Study, Journal Article)
• Copyright: © The Author(s) 2021. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Antiviral Agents

Topics

• Humans
• Antiviral Agents (therapeutic use)
• Hepacivirus
• Egypt (epidemiology)
• Hepatitis C, Chronic (drug therapy)
• Hepatitis C (drug therapy)
• Treatment Outcome